OmniAb Announces Agenda for its Research & Technology Virtual Event
31 Ottobre 2023 - 9:28PM
Business Wire
November 9th webcast to include a review of
third quarter 2023 financial results
OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its
Research & Technology virtual event to be held on Thursday,
November 9th beginning at 11:00 a.m. Eastern time. The two-hour
event will include an update on the company’s technology offerings,
a review of third quarter financial results, which will be
announced earlier that morning, and a Q&A session.
The agenda for the event is as follows:
- Business Overview and Updates – Matt Foehr, Chief Executive
Officer
- Creating Value for our Partners – Todd Pettingill, Vice
President, Business Development and Strategy
- Introducing the OmnidAb™ Technology – Bill Harriman, Ph.D., Sr.
Vice President, Antibody Discovery
- Enhancing Discovery with OmniDeep™ – Bob Chen, Ph.D., Sr.
Director, Discovery Systems
- The Ion Channel Opportunity – Doug Krafte, Ph.D., Sr. Vice
President, Ion Channels/Transporters
- Financial Updates – Kurt Gustafson, Chief Financial
Officer
Interested parties are requested to register in advance by
clicking here. The live and archived webcast, along with speaker
slides, will be available on the Investors portion of OmniAb’s
website.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications through a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. We believe the OmniAb animals
comprise the most diverse host systems available in the industry
and they are optimally leveraged through computational antigen
design and immunization methods, paired with high-throughput single
B cell phenotypic screening and mining of next-generation
sequencing datasets with custom algorithms to identify fully human
antibodies with superior performance and developability
characteristics. These proprietary technologies are joined with and
leverage OmniDeep™, which is a suite of in silico tools for
therapeutic discovery and optimization that are woven throughout
OmniAb’s various technologies and capabilities. Additionally, an
established core competency focused on ion channels and
transporters further differentiates OmniAb’s technology and creates
opportunities in many emerging target classes. OmniAb antibodies
have been leveraged across modalities, including bispecific
antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031545244/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com X (Twitter)
@OmniAbTech (510) 768-7760
Grafico Azioni OmniAb (NASDAQ:OABI)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni OmniAb (NASDAQ:OABI)
Storico
Da Ott 2023 a Ott 2024